I just Don't Understand How a Bottled e-Liquid could be assessed using the listed Criteria below when there is No Assurance that a User will Use it the way a Tester Tested it?
(1) A summary of the nonclinical and clinical studies relevant to your PMTA, regardless of whether you consider these studies favorable or unfavorable to the application. It would be helpful to include the specific product or products that were studied and how those products have similar characteristics (similar materials, ingredients, design, composition, heating source, or other features) to the applicant’s product if used as a substitute or supplement for data for the product. It would also be helpful to include the study findings, such as whether the findings concern the product’s health risks compared to other tobacco products and whether the product presents less risk than other tobacco products. If no relevant health information is available, we recommend that you state so in this section;
(2) The relative health risks of the new tobacco product for both users and nonusers compared to other tobacco products on the market (e.g., other ENDS, combusted tobacco products such as cigarettes), including tobacco products within the same product category as it may be expected that consumers of current products within the same product category may switch to using a newly marketed product, and the health risks compared to never using tobacco products;
(3) The chemical and physical identity and quantitative levels of the emission of aerosols under the range of operating conditions (e.g., various temperature, voltage, wattage settings) and use patterns (e.g., intense and non-intense use conditions) within which consumers are likely to use the new tobacco product;
(4) The likelihood, based on the research information contained in your application, of current nonusers of tobacco products initiating or reinitiating tobacco use by using the new tobacco product;
(5) The likelihood, based on the research information contained in your application, that consumers will adopt the new tobacco product and then switch to other tobacco products that may present higher levels of risk, such as cigarettes;
(6) The likelihood, based on the research information contained in your application, of consumers using the new tobacco product in conjunction with other tobacco products;
(7) The likelihood, based on the research information contained in your application, of current tobacco product users switching to the product instead of ceasing tobacco product use or using an FDA-approved tobacco cessation product (because use of ENDS products includes inherent risk above quitting altogether or the use of an FDA-approved nicotine-replacement therapy (NRT));
(8) Assessment of abuse liability (i.e., the addictiveness, abuse, and misuse potential of the new product and the exposure to nicotine during product use);
(9) Assessment of user topography (how individual users consume the product, e.g., the number of puffs, puff duration, puff intensity, duration of use), the frequency with which consumers use the product, and the trends by which users consume the product over time; and
(10) A discussion demonstrating how the data and information contained in your PMTA establish that permitting the marketing of the new tobacco product would be APPH.
https://www.fda.gov/media/127853/download
Now if I was say BT or NJOY, and my specific e-Liquid was tied to my Specific e-Cigarette, and I was tying to get a PMTA for them as when they are Used/Sold together, then yeah, that makes Sense.
There is also this...
c. Principles of operation
Consumers may be able to alter an ENDS product’s effects by changing the product design, the way the product is used, or adding or subtracting other ingredients. Section 910(b)(1)(B) of the FD&C Act requires you to submit as part of your PMTA “a full statement of the . . . principle or principles of operation” of the new tobacco product. FDA interprets a full statement of principle or principles of operation to include a full narrative description of the way in which a consumer will use the new tobacco product, including a description of how a consumer operates the product, how the manufacturer reasonably believes a consumer could change the product characteristics, adjust the performance, or add or subtract ingredients. This description also should include examples of the other types of ENDS products with which your product can be used and also show the range of conditions under which the product may operate.
https://www.fda.gov/media/127853/download
... which I am Not Sure how a Bottled e-Liquid could be assessed in an the Multitudes of Open System atomizers paired with 510 interchangeable Mods?
To just have a Bottle of e-Liquid, and Not be able to Evaluate it with a Specific e-Cigarette, and to Not be able to make any Assurances that the e-Liquid will ONLY be used with that specific e-Cigarette, seems like a Non-Starter for FDA Market Order-wise.
Not trying to be the Big Black Fly in the Wedding Cake. But whenever I read Anything the FDA published with the word "e-Liquid" in it, I Always took it in the context of an e-Liquid being used in a Specific e-Cigarette(s).